Related Experiment Videos
The integration of newer agents into neoadjuvant therapy
1Medical Oncology Service, University Hospital Germans Trias I Pujol, Badalona, Barcelona, Spain.
Seminars in Oncology
|August 15, 1998
Summary
Multimodality treatment, including induction chemotherapy with cisplatin, significantly improves survival for N2 non-small cell lung cancer patients. This approach is crucial for managing systemic disease and preventing relapse after surgery.
Area of Science:
- Oncology
- Thoracic Surgery
- Medical Oncology
Background:
- N2 non-small cell lung cancer (NSCLC) has a poor prognosis with surgery alone due to systemic micrometastases.
- Relapse is common in N2 NSCLC, necessitating advanced treatment strategies beyond surgical resection.
Purpose of the Study:
- To evaluate the efficacy of multimodality treatment, particularly induction chemotherapy, for N2 non-small cell lung cancer.
- To explore the role of cisplatin-based chemotherapy and novel agents in improving survival outcomes.
Main Methods:
- Review of randomized trials demonstrating the benefits of induction chemotherapy prior to surgery or radiotherapy.
- Analysis of complete resection and downstaging as survival surrogates.
- Discussion of ongoing trials incorporating docetaxel and molecular markers.
Main Results:
- Cisplatin-based induction chemotherapy significantly improves median and 5-year survival compared to surgery alone.
- Induction chemotherapy shows comparable benefits when preceding thoracic radiotherapy.
- Complete resection and downstaging of N2 disease are associated with improved long-term survival.
Conclusions:
- A multimodality approach combining chemotherapy, radiotherapy, and surgery is essential for N2 NSCLC.
- Cisplatin-based induction chemotherapy offers a survival advantage and potential cure for select stage IIIA patients.
- Future research should focus on earlier disease stages, novel agents like docetaxel, and molecular markers for personalized treatment.